Related Experiment Videos
Anticholinergic, antimuscarinic bronchodilators.
The American Review of Respiratory Disease
|May 1, 1984
Summary
Anticholinergic bronchodilators like ipratropium bromide offer effective, long-lasting airway relaxation with fewer side effects than atropine. They provide a complementary treatment option for obstructive airways diseases.
Area of Science:
- Pharmacology
- Respiratory Medicine
Background:
- Anticholinergic, antimuscarinic compounds are effective bronchodilators.
- Atropine has systemic side effects due to rapid absorption.
- Quaternary ammonium derivatives like ipratropium bromide are poorly absorbed and safer.
Purpose of the Study:
- To evaluate anticholinergic bronchodilators as an alternative and complementary treatment for airways obstruction.
- To compare the efficacy and side effect profile of ipratropium bromide with other bronchodilators.
Main Methods:
- Administration of anticholinergic bronchodilators via inhalation.
- Comparison of ipratropium bromide with atropine and beta 2-adrenergic agents.
- Assessment of bronchodilator effects in stable asthmatic subjects and patients with chronic bronchitis and emphysema.
Main Results:
- Inhaled ipratropium bromide is a potent and long-acting bronchodilator, comparable to or more potent than beta 2-adrenergic agents in certain conditions.
- Ipratropium bromide has a significantly better side effect profile than atropine, with minimal systemic effects.
- Combination therapy with ipratropium bromide enhances bronchodilatation.
- Ipratropium bromide is safe for patients with glaucoma and bladder neck obstruction.
Conclusions:
- Anticholinergic bronchodilators, particularly ipratropium bromide, represent a valuable therapeutic option for managing airways obstruction.
- Ipratropium bromide is well-suited for long-term management of chronic bronchitis and emphysema.
- It is also beneficial for asthmatic patients unresponsive or sensitive to adrenergic agents.